Potential Role of Ixekizumab in Plaque Psoriasis Treatment

Dear Dr. Renukaprasad A R, Psoriasis is a chronic immune-mediated skin disease that substantially burdens individuals and society. Genetics and immunological studies have identified interleukin-17A (IL-17A) as a critical driver in the development of psoriasis. Ixekizumab (IXE), a high-affinity interleukin-17A (IL-17A) monoclonal antibody, is effective and safe for moderate-to-severe plaque psoriasis patients with a rapid onset of action. Eli Lilly brings you renowned dermatology experts Dr. Diana Rubel (Australia), Dr. Sushil Tahiliani (India), and Dr. Kiran Godse (India) to discuss their learnings and experiences with IXE, followed by a live panel discussion on the effective use of IXE in Indian settings. Join us TODAY at 7:30 PM IST. We look forward to your presence in this discussion! Session highlights: Opening remarks Learnings and experiences with IXE  IXE in the Indian context - Panel discussion  Benefits of the AI (Auto-injector) device Click to Join Docplexus: One of the world's largest online communities of Doctors Pune - 411045, India info@docplexus.co.in�� |� +91 98500 36954 You are receiving this communication because you are registered member of Docplexus. Unsubscribe from this mailing list. *|LIST:DESCRIPTION|* *|LIST:ADDRESS|* *|REWARDS_TEXT|*